. Author manuscript; available in PMC: 2018 Jan 29.

Published in final edited form as: JAMA Cardiol. 2016 Dec 1;1(9):1066–1072. doi: 10.1001/jamacardio.2016.2132

Table 1.

Milestones in Oncocardiology

Year	Milestones
1963	Discovery of daunorubicin (1st anthracycline)^1,2
1966	Early report of anthracycline-induced cardiotoxic effects³
1977	Anthracycline cardiotoxic effects is dependent on the cumulative dose^4,63
1980	Efforts to reduce anthracycline-induced cardiotoxic effects through dose limitation, chemical protection, change in formulation, or change in delivery schedule⁶⁴
1998	Early report of trastuzumab (herceptin)-induced cardiotoxic effects²⁴
2007	Reports of multikinase inhibitors causing hypertension, heart failure, vascular occlusion⁴⁰
2012	Discovery of Topoisomerase IIβ as the molecular basis of anthracycline-induced cardiotoxic effects¹⁵